“It is unconscionable,” said one advocate welcoming the announcement, “for Medicare premiums to increase this dramatically because of one corporation’s greed.”
By Brett Wilkins. Pubished 1-10-2022 by Common Dreams
As the head of the U.S. Department of Health and Human Services announced Monday that he was ordering a review of a planned 15% hike in the Medicare Part B premium for 2022, healthcare reform advocates stressed the need for Congress to pass a Build Back Better bill with a provision allowing the federal government to negotiate the price of prescription drugs.
HHS Secretary Xavier Becerra said that he was instructing the Centers for Medicare and Medicaid Services (CMS) “to reassess the recommendation for the 2022 Medicare Part B premium”—a hike that progressive critics said was largely the result of the pharmaceutical industry’s outrageous profiteering. Continue reading